DEKA
31.1.2024 16:01:35 CET | Business Wire | Press release
DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics and surgery, on the occasion of the 25th IMCAS World Congress, which will be held in Paris from February 1-3, has announced the launch of 4 new laser platforms which integrate the “PRO” line, presented during the World Congress of Dermatology (WCD) held in Singapore last July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131482600/en/
(Photo: DEKA)
After the success obtained in the US and Canada, DEKA, with its laser systems, among which the very famous lunch-time CoolPeel® treatment for face rejuvenation, and epilation is now introducing the TETRA PROTM, MOTUS PROTM, SMARTXIDE PROTM and TOROTM platforms to the market.
With these new solutions DEKA transforms traditional dermatology laser technology paradigms, aesthetic medicine and dermatologic surgery, opening them to new practical frontiers.
Riccardo Stocchi – The company’s Innovation Manager stated: “The enthusiasm for the success we obtained with the PRO line and the ability to anticipate physicians’ requests, have turned, once again, into DEKA’s ability to create innovation, paying close attention to product positioning and correct segmentation of the reference market, responding with breakthrough technologies, which provide enormous benefits to both operators and patients. The road marked by DEKA, which has invested substantially in research and development and clinical research, obtaining extraordinary results, highlights, besides high efficacy and safety standards, maniacal attention to detail, from equipment design to software usability, with more and more innovative graphic user interfaces, which are absolutely intuitive and user friendly".
Paolo Salvadeo, DEKA’s CEO and El.En.’s General Manager, echoes Mr. Stocchi by adding: "These four new laser solutions, which see the light after few months from the launch of the PRO line, are the umpteenth demonstration of the efficacy of our organizational and R&D model. The path is marked. Thanks to DEKA’s strong aid, our group, in the medical segment, not only wishes to assert itself as the first player in the medical laser segment worldwide, but also to prospectively maintain a strong leadership position with regard to the market and competition. It is a fast-running machine, which we have no intention of slowing down".
Talking specifically about the four DEKA novelties, TETRA PROTM carries on the success seen by the birth of the “CoolPeel®” treatment/phenomenon in the US. TETRA PROTM, with its 40W of power, is the evolution of the 30W “SmartXide Tetra” CO2 laser, with a broader scanning area and treatment time reduction by 25%. The new “TETRA MOVEO” scanning mode also allows for treatment time reduction of the Made in the USA “CoolPeel®”. The ability to execute different treatments, from traditional and fractional rejuvenation, to various types of scar tissue, also deep, ultrafast vaporisations and other treatments which fall within various disciplines, completes the versatility of this new technology.
MOTUS PROTM is the latest evolution of the Motus line, Alexandrite laser and Nd:YAG, which has revolutionized the paradigms of epilation thanks to its high efficacy and very high comfort for the patient, also opening itself up to vascular treatments, up to the latest Made in the USA “MOVEO GLO”, which offers a complete face treatment, in the same session, to achieve optimal results at pigmentary, vascular and chrono-photo aging level. The “3 in 1” treatment with “GLO(W)” effect.
New design, more peak power, handled by a new software and mitigated by a new cooling system to carry forward the worldwide success in epilation signed by DEKA, are only a few of the novelties of the MOTUS PROTM technology.
Going back to CO2 Laser technology, SmartXide PROTM replicates the success of its predecessor, SmartXide DOT, the first fractional laser on the market, which has obtained success the world over, in particular in the United States, also known for periocular and blepharoplasty treatments.
Another important novelty is TOROTM, the laser device that the market had long been waiting for to act on more fronts: Spots, tattoos, rejuvenation, ranging from scar tissue to toning, all the way to the DEKAPeel treatment, to quickly intervene on dilated pores and obtain general improvement of cutaneous texture.
2 wavelengths, 1064 and 532 nm Q-Switched, and a third, 785nm, operating in the picosecond range, guarantee treatment efficacy and safety. TOROTM has been engineered especially for those skin types, among which Asian ones, which may benefit from this ultrafast coherent radiation, in terms of treatment efficacy and safety. By means of a pre-set database, which offers several clinical cases and a guided path throughout the various parameters which involve several targets (spot depth, tattoo color, typology of benign pigmented lesions, rejuvenation type and toning), TOROTM guides the physician, whilst guaranteeing treatment efficacy and safety.
Information on DEKA M.E.L.A.
DEKA M.E.L.A. is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients, and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
DEKA means reaching perfection and excellence and it is “10”, the perfect number according to the philosopher and mathematician Pythagoras.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131482600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 09:00:00 CEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 08:33:00 CEST | Press release
Global study of 276 practitioners across 22 countries defines the “Agentic Gap” and outlines how financial institutions can transition from experimentation to governed, high-impact deployment.Supporting analysis by Oliver Wyman finds reporting absorbs 1% to 3% of total bank expenditure, with a concentrated share of it addressable by agentic workflows. Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embe
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 20281 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements:Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 07:00:00 CEST | Press release
New portfolio combines high-performance cell culture media, molecule-specific CQA optimization, and integrated CDMO capabilities to help biosimilar developers accelerate the path to analytical similarity and improve process economics. OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of
H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications22.9.2026 06:00:00 CEST | Press release
The 700 kW system builds on H2SITE’s previous maritime deployments and is designed as a modular, replicable solution for auxiliary power onboard vessels H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/ Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry. Led by H2SITE, HydraNord
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
